Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eribulin + carboplatin
- Development stage
- Unknown
- Lead developer
- Eisai
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Eribulin + carboplatin is a combination chemotherapy regimen used primarily in the treatment of advanced or metastatic cancers, including breast cancer. Eribulin is a non-taxane microtubule dynamics inhibitor that acts by binding to a unique site on tubulin, suppressing microtubule polymerization and sequestering tubulin into nonfunctional aggregates. This leads to G2/M cell-cycle arrest and apoptosis after prolonged mitotic blockage. Carboplatin is a platinum-based chemotherapeutic agent that causes DNA crosslinking and inhibits DNA synthesis, leading to cell death. The combination has been studied for its efficacy in heavily pretreated patients with advanced cancers, showing feasibility and notable response rates[1][2][5][6].
- Brand names
- Halaven (for eribulin)
- Other names
- eribulin mesylatecarboplatin
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on eribulin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eribulin + carboplatin.